LAS VEGAS, Oct. 5, 2020
The factors like the expected entry of emerging therapies with novel targets and pricing are fueling the market. Also, upcoming products such as Adstiladrin, Vicinium, N-803, TLD-1433, CG0070 and Keytruda are anticipated to expand the market.
LAS VEGAS, Oct. 5, 2020 /PRNewswire/ -- DelveInsight's latest report on Non-Muscle Invasive Bladder Cancer Market also indicates that the tremendous growth of market size is because of the increased incident cases of NMIBC, imminent drug launches, increased diagnosis, upsurge in research and development, and enriched understanding of the disease.
Some key highlights from the report:
Non-Muscle Invasive Bladder Cancer is a common, heterogeneous disease associated with high recurrence rates. The cancer is found in the tissue that lines the bladder's inner surface, wherein the bladder muscle is not involved.
Approximately 70–80% of patients with newly diagnosed bladder cancer present with a form of Non-Muscle Invasive Bladder Cancer, such as non-invasive papillary tumour (pTa), carcinoma in situ (CIS; pTis), or early invasive tumour (non-muscle invasive; pT1). These tumours characteristically recur in 50–70% of cases, with only approximately 10–20% of cases progressing to muscle-invasive bladder cancer (MIBC).
The epidemiology for NMBIC is complex however DelveInsight's NMIBC report covers an in-depth epidemiological analysis and provides epidemiological forecasts upto 2030, segmented as the following: · Prevalent cases of Bladder Cancer
NMIBC remains a very challenging disease to treat with high rates of recurrence and progression associated with current therapies. The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC.
Historically Bacillus Calmette–Guarin (BCG) was the main treatment option for early bladder cancer i.e. high-risk NMIBC but more than 50-60% of patients become BCG unresponsive. Additionally, ongoing BCG shortage in addition to the lack of effective alternative drug therapies for patients with BCG-unresponsive disease, a large unmet need exists for these patients and providers. The treatment regimen includes surgery, intravesical immunotherapy, and intravesical chemotherapy. Intermediate- or high-risk NMIBC is generally treated with transurethral resection of bladder tumor (TURBT), followed by adjuvant BCG immunotherapy, which is the standard gold treatment for reducing tumor recurrence rates and preventing subsequent stage progression. However these are associated with many adverse side effects. Due to all these issues, there was a high unmet need for these patients until Keytruda got approved in 2020. Newer promising agents including gene therapies and fusion proteins are in pipeline, addressing these challenges. The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future. Some of the potential ones are:
Adstiladrin (nadofaragene firadenovec): is a gene therapy consisting of an adenovirus containing the gene interferon (IFN)-alpha2b. Things are on track for approval of gene therapy for early-stage bladder cancer i.e. High-risk BCG refractory NMIBC sooner as the latest data presented during ASCO GU symposium 2020 was very promising and even better in terms of efficacy and duration of response than only approved treatment i.e. Keytruda. It has got Priority Review; Fastrack; Breakthrough designation from USFDA already.
Keytruda: It is the first and only approved immune checkpoint inhibitor approved for high-risk non-muscle-invasive bladder cancer. It is expected to get stiff competition from Adstiladrin, a gene therapy that will share the same patient pool with Keytruda.
Vicinium: also known as VB4-845, is an antibody-drug conjugate (ADC), developed for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC). Vicinium is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A (ETA).
N-803 (ALT-803): is an interleukin-15 (IL-15) agonist, along with BCG looks another promising option for NMIBC patients
Emerging Drugs in NMIBC | Key Players involved
Key Trends of Non-Muscle Invasive Bladder Cancer Market Report: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
Scope of the Report
Table of Contents
1 Key Insights
2 Executive Summary of Non-Muscle Invasive Bladder Cancer
3 Non-Muscle Invasive Bladder Cancer SWOT Analysis
4 Non-Muscle Invasive Bladder Cancer Market Overview at a Glance
5 Disease Background and Overview: Non-Muscle Invasive Bladder Cancer
6 Recognized Establishments
7 Non-Muscle Invasive Bladder Cancer Epidemiology and Patient Population
8 7MM Total Diagnosed NMIBC Prevalent cases
9 7MM NMIBC Epidemiology
9.1 United States
9.2 EU5 Countries
9.7 United Kingdom
10 Non-Muscle Invasive Bladder Cancer Treatment
11 Unmet Needs
12 Non-Muscle Invasive Bladder Cancer Marketed Drugs
12.1 Keytruda (pembrolizumab): Merck
12.2 Valstar (valrubicin): Endo Pharmaceuticals
13 Non-Muscle Invasive Bladder Cancer Emerging Drugs
13.1 Vicinium: Sesen Bio
13.2 Adstiladrin (nadofaragene firadenovec/Syn3): FKD Therapies Oy/ Ferring Pharmaceuticals
13.3 Tecentriq (atezolizumab): Hoffmann-La Roche
13.4 Sasanlimab (PF-06801591) + BCG: Pfizer
13.5 Apaziquone: Spectrum Pharmaceuticals
13.6 Opdivo (nivolumab): Bristol-Myers Squibb
13.7 Imfinzi (durvalumab): AstraZeneca
13.8 VesiGel (UGN-102/mitomycin gel): UroGen Pharma
13.9 Pemigatinib: Incyte Corporation
13.10 CG0070: CG Oncology
13.11 Erdafitinib: Janssen Research & Development
13.12 Revlimid (lenalidomide): Celgene Corporation/Bristol-Myers Squibb
13.13 N-803 (ALT-803): ImmunityBio/Altor Biosciences
13.14 TLD-1433: Theralase
13.15 Bavencio (avelumab + BCG): EMD Serono
13.16 Alpha1H: Hamlet Pharma
13.17 LiPax: TesoRx Pharma
13.18 Imfinzi (durvalumab) + S-488210/S-488211: AstraZeneca
14 Non-muscle Invasive Bladder Cancer 7 Major Market Analysis
15 Attribute Analysis
16 Key Non-Muscle Invasive Bladder Cancer Market Assumptions
17 7MM NMIBC Market Outlook
17.1 United States NMIBC Market Size
17.6 United Kingdom
17.7 Japan NMIBC Market Size
18 Access and Reimbursement
19 Case Reports
20 Non-Muscle Invasive Bladder Cancer Market Drivers
21 Non-Muscle Invasive Bladder Cancer Market Barriers
23 DelveInsight Capabilities
25 About DelveInsight
Browse Detailed TOC, Tables, Figures, Emerging Drugs and Companies @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
Reasons to buy
Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
Non Muscle Invasive Bladder Cancer Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.